MAPT and Alzheimer disease: Enhanced NDEV levels of P-T181-tau, P-S396-tau, and Aβ42 were also found to predict the development of AD up to 10 years before clinical diagnosis [11] while increased NDEV Aβ42 levels in MCI subjects have been associated with an 8.5-fold greater risk of developing AD dementia [20].